What Is Known About Polio’s Return to the Gaza Strip 

Displaced kids sort through trash at a street in Deir al-Balah, central Gaza Strip, Tuesday, Aug. 27, 2024. (AP)
Displaced kids sort through trash at a street in Deir al-Balah, central Gaza Strip, Tuesday, Aug. 27, 2024. (AP)
TT

What Is Known About Polio’s Return to the Gaza Strip 

Displaced kids sort through trash at a street in Deir al-Balah, central Gaza Strip, Tuesday, Aug. 27, 2024. (AP)
Displaced kids sort through trash at a street in Deir al-Balah, central Gaza Strip, Tuesday, Aug. 27, 2024. (AP)

Health authorities in the Gaza Strip confirmed the first case of polio in 25 years earlier this month.

The infection and subsequent partial paralysis of the nearly year-old Abdul-Rahman Abu Al-Jidyan has hastened plans for a mass vaccination campaign of children across the Palestinian enclave starting on Sept. 1.

Three-day pauses in fighting in each of Gaza's three zones have been agreed by Israel and Hamas to allow thousands of UN workers to administer vaccines.

ORIGINS

The same strain that later infected the Palestinian baby, from the type 2 vaccine-derived polio virus that has also been detected in wastewater in some developed countries in recent years, was detected in July in six sewage samples taken in Khan Younis and Deir al-Balah.

It is not clear how the strain arrived in Gaza but genetic sequencing showed that it resembles a variant found in Egypt that could have been introduced from September 2023, the WHO said.

The UN health body says that a drop in routine vaccinations in the Occupied Palestinian Territories, including Gaza, has contributed to its re-emergence.

Polio vaccination coverage, primarily conducted through routine immunization, was estimated at 99% in 2022 and fell to 89% in 2023. Health workers say the closure of many hospitals in Gaza, often because of Israeli strikes or restrictions on fuel, has contributed to lower vaccination rates. Israel blames Hamas, saying they use hospitals for military purposes.

Aid workers say poor sanitation conditions in Gaza where open sewers and trash piles are commonplace after nearly 11 months of war have created favorable conditions for its spread.

MASS VACCINATIONS

Israel's military and the Palestinian armed group Hamas have agreed to three separate, zoned three-day pauses in fighting to allow for the first round of vaccinations.

The campaign is due to start in central Gaza on Sunday with three consecutive daily pauses in fighting, then move to southern Gaza, where there would be another three-day pause, followed by northern Gaza. There is an agreement to extend the pause in each zone to a fourth day if needed.

The vaccines, which were released from global emergency stockpiles, have already arrived in Gaza and are due to be issued to 640,000 children under 10 years of age.

They will be given orally by some 2,700 health care workers at medical centers and by mobile teams moving among Gaza's hundreds of thousands of people displaced by the war, UN aid workers say.

The World Health Organization says that a successful roll-out requires at least 95% coverage.

The Israeli military's humanitarian unit (COGAT) said that the vaccination campaign would be conducted in coordination with the Israeli military "as part of the routine humanitarian pauses that will allow the population to reach the medical centers where the vaccinations will be administered".

A second round is planned in late September.

RISKS

The Gaza case which is vaccine-derived is seen as a setback for the global polio fight which has driven down cases by more than 99% since 1988 thanks to mass vaccination campaigns.

Wild polio is now only endemic in Pakistan and Afghanistan although more than 30 countries are still listed by the WHO as subject to outbreaks, including Gaza's neighbors Egypt and Israel.

The World Health Organization has warned of the further spread of polio within Gaza and across borders given the poor health and hygiene conditions there.

Poliomyelitis, which is spread mainly through the faecal-oral route, is a highly infectious virus that can invade the nervous system and cause paralysis and death in young children with those under 2 years old most at risk. In nearly all cases it has no symptoms, making it hard to detect.



New Mpox Strain Is Changing Fast; African Scientists Are ‘Working Blind’ to Respond 

Dr. Robert Musole, medical director of the Kavumu hospital (R) consults an infant suffering from a severe form of mpox at the Kavumu hospital, 30 km north of Bukavu in eastern Democratic Republic of Congo, August 24, 2024. (AFP)
Dr. Robert Musole, medical director of the Kavumu hospital (R) consults an infant suffering from a severe form of mpox at the Kavumu hospital, 30 km north of Bukavu in eastern Democratic Republic of Congo, August 24, 2024. (AFP)
TT

New Mpox Strain Is Changing Fast; African Scientists Are ‘Working Blind’ to Respond 

Dr. Robert Musole, medical director of the Kavumu hospital (R) consults an infant suffering from a severe form of mpox at the Kavumu hospital, 30 km north of Bukavu in eastern Democratic Republic of Congo, August 24, 2024. (AFP)
Dr. Robert Musole, medical director of the Kavumu hospital (R) consults an infant suffering from a severe form of mpox at the Kavumu hospital, 30 km north of Bukavu in eastern Democratic Republic of Congo, August 24, 2024. (AFP)

Scientists studying the new mpox strain that has spread out of Democratic Republic of Congo say the virus is changing faster than expected, and often in areas where experts lack the funding and equipment to properly track it.

That means there are numerous unknowns about the virus itself, its severity and how it is transmitting, complicating the response, half a dozen scientists in Africa, Europe and the United States told Reuters.

Mpox, formerly known as monkeypox, has been a public health problem in parts of Africa since 1970, but received little global attention until it surged internationally in 2022, prompting the World Health Organization to declare a global health emergency. That declaration ended 10 months later.

A new strain of the virus, known as clade Ib, has the world's attention again after the WHO declared a new health emergency.

The strain is a mutated version of clade I, a form of mpox spread by contact with infected animals that has been endemic in Congo for decades. Mpox typically causes flu-like symptoms and pus-filled lesions and can kill.

Congo has had more than 18,000 suspected clade I and clade Ib mpox cases and 615 deaths this year, according to the WHO. There have also been 222 confirmed clade Ib cases in four African countries in the last month, plus a case each in Sweden and Thailand in people with a travel history in Africa.

"I worry that in Africa, we are working blindly," said Dr. Dimie Ogoina, an infectious diseases expert at Niger Delta University Hospital in Nigeria who chairs the WHO's mpox emergency committee. He first raised the alarm about potential sexual transmission of mpox in 2017, now an accepted route of spread for the virus.

"We don’t understand our outbreak very well, and if we don't understand our outbreak very well, we will have difficulty addressing the problem in terms of transmission dynamics, the severity of the disease, risk factors of the disease," Ogoina said. "And I worry about the fact that the virus seems to be mutating and producing new strains."

He said it took clade IIb in Nigeria five years or more to evolve enough for sustained spread among humans, sparking the 2022 global outbreak. Clade Ib has done the same thing in less than a year.

MUTATING 'MORE RAPIDLY'

Mpox is an orthopoxvirus, from the family that causes smallpox. Population-wide protection from a global smallpox vaccine campaign 50 years ago has waned, as the vaccinating stopped when the disease was eradicated.

Genetic sequencing of clade Ib infections, which the WHO estimates emerged mid-September 2023, show they carry a mutation known as APOBEC3, a signature of adaptation in humans.

The virus that causes mpox has typically been fairly stable and slow to mutate, but APOBEC-driven mutations can accelerate viral evolution, said Dr. Miguel Paredes, who is studying the evolution of mpox and other viruses at Fred Hutchison Cancer Center in Seattle.

"All the human-to-human cases of mpox have this APOBEC signature of mutations, which means that it's mutating a little bit more rapidly than we would expect," he said.

Paredes and other scientists said a response was complicated by several mpox outbreaks happening at once.

In the past, mpox was predominantly acquired through human contact with infected animals. That is still driving a rise in Congo in clade I cases – also known as clade Ia - likely due in part to deforestation and increased consumption of bushmeat, scientists said.

The mutated versions, clade Ib and IIb, can now essentially be considered a sexually transmitted disease, said Dr. Salim Abdool Karim, a South African epidemiologist and chair of the Africa CDC’s mpox advisory committee. Most of the mutated clade Ib cases are among adults, driven at first by an epidemic among female sex workers in South Kivu, Congo.

The virus also can spread through close contact with an infected person, which is likely how clusters of children have been infected with clade Ib, particularly in Burundi and in eastern Congo’s displacement camps, where crowded living conditions may be contributing.

Children, pregnant women and people with weakened immune systems or other illnesses may be at greater risk of serious mpox disease and death, say the WHO and mpox scientists.

Clade I has typically caused more severe disease, with fatality rates of 4%-11%, compared to around 1% for clade II. Ogoina said data from Congo suggests few have died of the new Ib version, but he feared some data is being mixed up.

More research is urgently needed, but three teams tracking mpox outbreaks in Africa say they cannot even access chemicals needed for diagnostic tests. Clade Ib can also be missed by some diagnostic tests.

Planning a response, including vaccination strategies, without this is difficult, the scientists said.

Karim said around half of cases in eastern Congo, where Ib is particularly prevalent, are only being diagnosed by doctors, with no laboratory confirmation.

Getting samples to labs is difficult because the healthcare system is already under pressure, he said. And around 750,000 people have been displaced amid fighting between the M23 rebel group and the government.

Many African laboratories cannot get the supplies they need, said Dr. Emmanuel Nakoune, an mpox expert at the Institut Pasteur in Bangui, Central African Republic, which also has clade Ia cases.

"This is not a luxury," he said, but necessary to track deadly outbreaks.